# Safety and Efficacy of Liposomal Amphotericin B for Patients With Invasive Mold Diseases in Liver Transplant Recipients

> **NCT07725874** · NA · NOT_YET_RECRUITING · sponsor: **Beijing Friendship Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Invasive Mold Diseases

## Interventions

- **DRUG:** AmBisome (Amphotericin B) Liposome

## Key facts

- **NCT ID:** NCT07725874
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-08
- **Primary completion:** 2028-05-15
- **Final completion:** 2028-08-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07725874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07725874, "Safety and Efficacy of Liposomal Amphotericin B for Patients With Invasive Mold Diseases in Liver Transplant Recipients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07725874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*